









Markets
/
Stocks
/
nasdaq-cbus
/

Cibus Inc

CBUS

1.420USD

+0.070+5.19%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

74.52MMarket Cap

LossP/E TTM



Cibus Inc

1.420

+0.070+5.19%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

133 / 207

Overall Ranking

331 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

14.400

Target Price

+966.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2614.65% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.26M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1388.30.

Overvalued

The company’s latest PE is -0.14, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 29.20M shares, increasing 31.46% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 856.15K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.12.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.23, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 933.00K, representing a year-over-year increase of 11.34%, while its net profit experienced a year-over-year increase of 1.97%.

Score

Industry at a Glance

Previous score

5.23

Change



Financials

4.03

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.48

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -0.13, which is 6.66% below the recent high of -0.14 and -28.17% above the recent low of -0.17.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 133/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.50, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Cibus Inc is 15.50, with a high of 25.00 and a low of 1.60.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

14.400

Target Price

+966.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Cibus Inc

CBUS

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.01, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.52 and the support level at 1.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.01

Change

0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.030

Neutral

RSI(14)

53.584

Neutral

STOCH(KDJ)(9,3,3)

47.862

Neutral

ATR(14)

0.080

High Vlolatility

CCI(14)

118.595

Buy

Williams %R

32.308

Buy

TRIX(12,20)

-0.178

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.370

Buy

MA10

1.371

Buy

MA20

1.347

Buy

MA50

1.453

Sell

MA100

1.761

Sell

MA200

2.123

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 60.37%, representing a quarter-over-quarter increase of 51.34%. The largest institutional shareholder is The Vanguard, holding a total of 856.15K shares, representing 1.63% of shares outstanding, with 46.47% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Riggs (Rory B)

14.63M

+396.82%

Fidelity Management & Research Company LLC

4.60M

+16.38%

JPL Investments SA

1.67M

-0.73%

Vantage Consulting Group, Inc.

1.14M

The Vanguard Group, Inc.

Star Investors

892.12K

+4.90%

BlackRock Institutional Trust Company, N.A.

1.03M

-1.59%

Beetham (Peter Ronald)

382.44K

Gocal (Gregory Francis William)

374.84K

+19.06%

Geode Capital Management, L.L.C.

473.61K

+20.70%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.03, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.73. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.